• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Success rates and timelines of recently studied viral vaccine candidates

byThomas SuandDeepti Shroff Karhade
December 7, 2020
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The overall probability of progression from phase 2 trials to FDA approval within 10 years was 1 in 10.

2. The average time from phase 2 to licensure was roughly four and a half years, although this period ranged from mere weeks to over a decade.

Evidence Rating Level: 2 (Good)

Study Rundown: With nearly 30 of 50 candidates advancing to phase 2 testing within months and multiple companies (Pfizer, Moderna, and AstraZeneca) already unveiling preliminary results from phase 3 trials, the development of vaccines against SARS-CoV-2 has been proceeding at breakneck pace. Despite these highly promising results, success is far from certain; one possibility that must be considered is the occurrence of various unanticipated setbacks such as vaccine-dependent enhancement, an effect that may not be immediately evident. While previous studies have examined some potential variables affecting the pace and probability of success of vaccine development, those were generally performed using clinical data from the previous decade. In order to account for the impact of recent technological advances such as next-generation sequencing and angstrom-resolution imaging, this study investigated all vaccines for emerging and reemerged viral infectious diseases (EVIDs) with clinical trials of any phase since 2005, a year which marked the inception of several new vaccine development approaches. After accounting for over 20 EVIDs, under 80 vaccines were found to have completed phase 1. Of these, only 9 ultimately advanced to approval, the fastest timeline being under 2 months and the slowest reaching nearly 14 years. While the overall probability of success (POS) within 10 years was 1 in 10, the exclusion of pandemic influenza trajectories lowered this number to only 1 in 30. This study offered a broad overview of the success probabilities and timelines of vaccines against viral diseases, but further research is needed to identify specific factors influencing movement through the development pipeline.

Click here to read the study in Annals of Internal Medicine

Relevant Reading: Clinical development success rates for investigational drugs

In-Depth [retrospective cohort]: This study utilized public data from ClinicalTrials.gov between 1 January 2005 and 22 March 2020 to identify 606 prelicensure trials involving 220 vaccine candidates. Only 76 candidates qualified for the primary analysis by progressing beyond phase 1, which reduced the the number of resolvable EVIDS from 27 to 23 (HIV, H5N1, Ebola, H1N1, H7N9, Zika, Universal flu, EV71, Dengue, West Nile, Chikungunya, H3N2v, Hepatitis C, Marburg, MERS, Smallpox, Yellow fever, Hantavirus, CCHF, H10N8, Lassa, Nipah, and Rift Valley). Of these 76 trajectories, only 9 were ever approved (shortest timeline, 6.4 weeks; longest timeline, 13.9 years), and only 7 were approved within 10 years of phase 2 start, corresponding to a Kaplan-Meier estimate of the POS of 10.0% (95% CI, 2.6% to 16.9%). After excluding pandemic influenza trajectories which primarily capitalized on an existing platform, the POS was reduced to merely 3.2% (CI, 0.0% to 9.2%). The probabilities of transition from phase 1 to phase 2 and from phase 2 to phase 3 were similar (38.2% [CI, 30.7% to 45.0%] versus 38.3% [CI, 23.1% to 50.5%]), but 61.1% (CI, 3.7% to 84.3%) of candidates that reached phase 3 were eventually granted approval. Vaccine type was found to have a major effect on POS, with only split virus vaccines (POS, 56.4%; CI, 12.6% to 78.2%) and nucleic acid vaccines (POS, 5.9%; CI, 0.0% to 16.4%) obtaining licensure within 10 years.

RELATED REPORTS

National survey reports parental views on COVID-19 vaccination in children

Tdap vaccine during pregnancy not linked to adverse childhood health outcomes

#VisualAbstract: Special Report: Vaccines in Development- Johnson & Johnson vaccine as another frontrunner

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: immunizationvaccinesviral illness
Previous Post

Masks for personal protection for SARS-CoV-2 infection

Next Post

2 Minute Medicine Rewind December 7, 2020

RelatedReports

Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

National survey reports parental views on COVID-19 vaccination in children

September 14, 2021
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

Tdap vaccine during pregnancy not linked to adverse childhood health outcomes

April 19, 2021
#VisualAbstract: Cabotegravir plus rilpivirine given every 8 weeks is non-inferior to every 4 weeks for maintenance of HIV-1 viral suppression
StudyGraphics

#VisualAbstract: Special Report: Vaccines in Development- Johnson & Johnson vaccine as another frontrunner

January 5, 2021
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

Appropriate knowledge of HPV vaccine important for uptake among college-age young adults

September 26, 2020
Next Post
Medical home linked to lower pediatric readmission rate

2 Minute Medicine Rewind December 7, 2020

Pediatric palliative care outcome measures often miss quality of life

Vitamin B12 supplementation not associated with improved outcomes in stunted children

Significant financial concerns associated with individuals with Alzheimer’s Disease and related dementias

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Sleep
  • Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events
  • Early onset Lewy Body Dementia is more clinically distinct from Alzheimer Dementia than late onset Lewy Body Dementia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.